Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter phase II randomized trial

Trial Profile

Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter phase II randomized trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Colon cancer
  • Focus Adverse reactions
  • Acronyms LEANOX
  • Most Recent Events

    • 20 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top